Scientists hunt for clues to predict chemo success in rare sarcomas
NCT ID NCT04008238
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 28 times
Summary
This study aimed to find biological markers (biomarkers) that could predict how well the drug trabectedin works in people with advanced soft-tissue sarcomas (excluding certain types). Researchers collected tumor biopsies and blood samples from 29 adult patients to analyze genetic and molecular features. The goal was to better understand which patients might benefit from trabectedin, rather than testing a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOID SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Bergonie
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.